乳腺癌大分割放疗的实施与利用
该研究在大型多中心放疗科评估临床指令作为默认治疗决策及前瞻性勾画查房对全乳大分割放疗实施的影响。ASTRO endorsed组(n=685)大分割使用率从2011年49%升至2015年80%,指令 endorsed组(n=1042)从47%升至73%。作者认为大分割仍未被充分利用,尽管局部控制等效、毒性更优且晚期效应非劣。
要点
- ASTRO endorsed组大分割使用率2011年49%、2015年80%。
- 指令 endorsed组大分割使用率2011年47%、2015年73%。
- 作者认为共识治疗指令、教师同行评审和财务领导力可能促成高使用率。
核心结论
- 大分割放疗仍未被充分利用,尽管其局部控制等效、毒性更优且晚期效应非劣。
- 本研究显示在大型多站点门诊环境中可实现高使用率。
- 作者认为可能的原因包括共识治疗指令建立的默认规则、教师同行评审以及在有指征时实施大分割的强有力财务领导力。
研究设计与样本
- 2010年实施共识驱动、证据为基础的临床指令指导治疗决策,共5条指令可用于乳腺癌辅助治疗。
- 2012年设立前瞻性勾画查房,由治疗医师展示指令选择和患者勾画以供同行评审和共识意见。
- 本研究报告共识别1043例乳腺癌病例,对早期乳腺癌患者病历进行回顾分析。
- 接受大分割的患者依据ASTRO 2011指南及对本中心更宽泛临床指令的依从性进行分析。
主要发现
- ASTRO endorsed组(n=685)接受大分割的患者2011年为49%,2015年为80%。
- 指令 endorsed组(n=1042)接受大分割的患者2011年为47%,2015年为73%。
关键数值与推荐
- ASTRO endorsed组n=685,2011年大分割使用率49%,2015年80%。
- 指令 endorsed组n=1042,2011年大分割使用率47%,2015年73%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypofractionation (HF) of whole breast irradiation has become a standard treatment regimen because randomized trials continue to demonstrate equivalence in survival and local control compared with conventional fractionation. In 2011, the American Society for Radiation Oncology (ASTRO) adopted clinical guidelines on the proper selection of HF. Nevertheless, utilization remains lower than predicted. We evaluate the effects of clinical directives that serve as default treatment decisions and prospective contouring rounds on the implementation of HF in a large, multicenter radiation oncology department. METHODS AND MATERIALS: In 2010, we implemented consensus-driven and evidence-based clinical directives to guide treatment decisions. Five directives were available for adjuvant breast cancer treatment, including conventional fractionation and HF approaches, and were selected on the basis of disease specifics and clinical judgment. In 2012, we instituted prospective contouring rounds wherein the treating physicians presented their directive selection and patient contours for peer-review and consensus opinion. For this study, charts for patients with early stage breast cancer were reviewed. A total of 1043 cases of breast cancer were identified. Patients receiving HF were analyzed on the basis of the ASTRO 2011 guidelines and adherence to our more inclusive clinical directives. RESULTS: For the ASTRO-endorsed group (n = 685), 49% of patients received HF in 2011, and 80% received HF in 2015. For the directives-endorsed group (n = 1042), 47% of patients received HF in 2011, and 73% received HF in 2015. CONCLUSIONS: HF is underutilized despite equivalent local control, superior toxicity profile, and noninferior late effects. Our study demonstrates the possibility of achieving high levels of utilization in a large, multisite, outpatient setting. Factors responsible may include default rules established through the development of consensus-based treatment directives, peer review by faculty, and strong financial leadership to implement HF when indicated. To our knowledge, this is the first example of combining both consensus-based treatment directives and prospective contouring rounds in an attempt to change practice patterns.
引用
- Gilbo P, Potters L, Lee L, et al. Implementation and utilization of hypofractionation for breast cancer. Adv Radiat Oncol. 2018. PMID: 30202795. doi:10.1016/j.adro.2018.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。